Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSKIN.L Regulatory News (SKIN)

  • There is currently no data for SKIN

Trading Update

15 Nov 2018 07:00

RNS Number : 4061H
Integumen PLC
15 November 2018
 

 

15 November 2018

 

Integumen plc

 

("Integumen" or "the Company")

 

Trading Update

 

 

The Company is pleased to announce the increased growth in product sales and contract test services at Labskin (Innovenn Limited, a wholly-owned subsidiary of Integumen plc).

 

With improved visibility ahead, the Company is on track to meet or exceed double the Group's revenues from the 2017 (£238,000) level. This is as a result of increased sales of STOER For Men skin products and the reduced marketing spend, leading to the current monthly break-even in the Skin Care division.

 

Major Restructuring:

 

Labskin, the trading name of Innovenn Limited, has undergone a major restructuring due to the acceleration of sales and services since H1 2018. A new website is now live at www.labskin.co.uk and reflects the new services being provided to its existing and new client base. Clients range from early start-up biotech companies to Fortune 100 companies with household name, health and cosmetic, brands.

 

Positive Results:

 

Improved revenue since July 2018 from Labskin has already been reported back in September as multiples of the entire H1 2018 reported sales (£49,000). Monthly sales continue to improve and further information on these improvements and expectation of where additional revenues are expected to come from are outlined below.

 

Artificial Intelligent Skin Care:

 

The recently announced collaboration with Venn Life Sciences Holdings plc and RinoLab, expected to go live shortly, delivers an integrated Artificial Intelligent product development platform for clients that allow validation of the impact of their product on the good and bad bacteria on human skin.

 

Balanced Microbiome Labskin Certified:

 

Confirmation of Labskin test results showing a balanced microbiome that contributes a positive outcome to skin treatment can now be certified for our clients' cosmetic and skin care products.

 

First Labskin Certified Range of Cosmetics:

 

STOER For Men, a skin care range of products owned by Integumen, are the first skin care products that have been certified as having a positive contribution to balancing skin's microbiome. They will be sold with the Labskin Certification. The low sales of STOER skin care products, with a high cost of sales, in H1 have improved in H2 2018. Monthly sales of STOER are at breakeven and expected to continue to improve into 2019.

 

Association of Labskin Certified Technicians:

 

Preparations are underway to roll out the Association of Labskin Certified Technicians (ALCT). Workshops and courses will commence in Q1 2019. Interest for certification already exists from our recent and new clients. These applied certified course programs serve to improve the expertise of our clients' in-house Labskin scientists, and increases the exposure of the Labskin brand test platform across the skin, health, topical drug delivery and wound care sectors.

 

New Appointments and Promotions:

 

Head of Labskin Operations:

 

Alex Chapman, has been promoted to lead an expanding team at Labskin. Alex joined Labskin in 2017 and was until recently General Manager of the Labskin team. This has now expanded in both production and tissue culture departments with a number of additional personnel since August. Labskin will add up to 40% more laboratory space in 2019 and Alex will also oversee external contract providers of third party-services which allows Labskin to provide a fully inclusive pre-clinical service solution to our clients.

 

Laboratory & Operations Manager:

 

Rupert Petch joins the Labskin team as laboratory and operations manager. Rupert worked as Project Manager for Fera Science Limited and its former company name of CSL (Central Science Laboratory) for almost 19 years. He is overseeing the expansion of the laboratory team and building on the solid foundation of quality controls to meet the highest standards required of our increasing client base.

 

 

Gerard Brandon (Chief Executive Officer) commented:

"In just the last 3 months the improvement of the Labskin and STOER Skin Care divisions have been transformational. Sales have accelerated and costs have reduced to breakeven in the skincare section. Labskin's new high margin services have seen higher demand with improved revenues from cosmetic, skin, health and wound care companies. There is good visibility of orders for the months ahead. Recent collaboration partners allow Labskin to roll out new products and value added services faster to our existing and new clients. This boost in sales has resulted in a need to add team members to support the increasing demand."

 

Integumen plc

Gerard Brandon, CEO

 

+44 (0) 122 392 6660

SPARK Advisory Partners Limited

(Nominated Adviser)

 

Neil Baldwin/Andrew Emmott

+44 (0) 113 370 8974

Hybridan LLP (Broker)

Claire Noyce

+44 (0) 20 3764 2341

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTKMMMMLDDGRZM
Date   Source Headline
2nd May 201910:51 amRNSHolding(s) in Company
2nd May 20198:18 amRNSBoard Appointment & Admission of Shares
1st May 201911:00 amRNSChanges to interests of a significant shareholder
30th Apr 20191:18 pmRNSResult of General Meeting
25th Apr 20197:01 amRNSTurner Pope Investor Evening
25th Apr 20197:00 amRNSLaunch of New Animal-Free Labskin Dandruff Test
12th Apr 20197:00 amRNSAcquisition of RinoCloud, Placing to raise £2.518m
25th Mar 20197:00 amRNSCBD tests boost procollagen and reduce irritation
21st Mar 20198:45 amRNSExercise of Warrants - Replacement
21st Mar 20197:01 amRNSExercise of Warrants
21st Mar 20197:00 amRNSLabskin:addl workspace at DHEZ Bradford University
18th Mar 20197:00 amRNSChange of Adviser
13th Mar 20194:35 pmRNSPrice Monitoring Extension
13th Mar 20197:00 amRNSExercise of Options
12th Mar 201910:51 amRNSShare Price Movement
11th Mar 20192:05 pmRNSSecond Price Monitoring Extn
11th Mar 20192:00 pmRNSPrice Monitoring Extension
5th Mar 20194:40 pmRNSSecond Price Monitoring Extn
5th Mar 20194:35 pmRNSPrice Monitoring Extension
5th Mar 20197:01 amRNSIssue of Equity
5th Mar 20197:00 amRNSAcqn of specialist equipment for Labskin's lab
25th Feb 20192:05 pmRNSSecond Price Monitoring Extn
25th Feb 20192:00 pmRNSPrice Monitoring Extension
22nd Feb 20192:05 pmRNSSecond Price Monitoring Extn
22nd Feb 20192:00 pmRNSPrice Monitoring Extension
21st Feb 201911:05 amRNSSecond Price Monitoring Extn
21st Feb 201911:00 amRNSPrice Monitoring Extension
20th Feb 20197:00 amRNSLabskin CBD tests
8th Feb 20197:00 amRNSRollout of Labskin AI Software as a Service begins
7th Feb 20197:00 amRNSChanges to interests of a significant shareholder
23rd Jan 20197:41 amRNSHolding(s) in Company
7th Jan 20197:00 amRNSTrading Update
18th Dec 20187:00 amRNSDivestment of TSPro GmbH
13th Dec 20187:00 amRNSLabskin-On-A-Chip
11th Dec 20181:20 pmRNSIssue of Equity
7th Dec 201812:46 pmRNSResult of Meeting
22nd Nov 20187:00 amRNSSubscription/ Placing to raise £355k, Notice of GM
15th Nov 20182:05 pmRNSSecond Price Monitoring Extn
15th Nov 20182:00 pmRNSPrice Monitoring Extension
15th Nov 20187:00 amRNSTrading Update
1st Nov 20187:00 amRNSCompletion of acq'n of interest in Cellulac plc
11th Oct 20187:00 amRNSUpdate on Placing and Subscription
27th Sep 20183:15 pmRNSUpdate :Placing&Subscription;Trading Announcement
20th Sep 20189:57 amRNSReplacement:legal demand; Placing and Subscription
19th Sep 20187:00 amRNSDetail of legal demand;Placing/Subscription update
17th Sep 20187:00 amRNSFirst laboratory-grown human-skin test service
29th Aug 20187:00 amRNSInterim Results
9th Aug 20184:34 pmRNSResult of AGM
3rd Aug 20183:22 pmRNSShare Purchase Agreement signed; Issue of shares
2nd Aug 20182:57 pmRNSResult of Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.